Screener
AbCellera Biologics Inc. ABCL Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:ReceivablesNetCurrent.
The source filing: AbCellera Biologics Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:28 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001703057-26-000046
FAQ
- What is AbCellera Biologics Inc.'s accounts receivable?
- AbCellera Biologics Inc. (ABCL) reported accounts receivable of $38.42M in Q2 2026.
- How has AbCellera Biologics Inc.'s accounts receivable changed year-over-year?
- AbCellera Biologics Inc.'s accounts receivable decreased by 45.1% year-over-year, from $70.01M to $38.42M.
- What is the long-term trend for AbCellera Biologics Inc.'s accounts receivable?
- Over 2 years (2020 to 2025), AbCellera Biologics Inc.'s accounts receivable has grown at a 560.6% compound annual growth rate (CAGR), from $903K to $39.41M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.
Ask your AI about AbCellera Biologics Inc.'s accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude